Skip to main page content
U.S. flag
See More

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1998 Mar;4(3):321-7.
doi: 10.1038/nm0398-321.

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

S A Rosenberg  1 , J C Yang, D J Schwartzentruber, P Hwu, F M Marincola, S L Topalian, N P Restifo, M E Dudley, S L Schwarz, P J Spiess, J R Wunderlich, M R Parkhurst, Y Kawakami, C A Seipp, J H Einhorn, D E White
Affiliations
Clinical Trial

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

S A Rosenberg et al. Nat Med. 1998 Mar.

Abstract

The cloning of the genes encoding cancer antigens has opened new possibilities for the treatment of patients with cancer. In this study, immunodominant peptides from the gp100 melanoma-associated antigen were identified, and a synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma. On the basis of immunologic assays, 91% of patients could be successfully immunized with this synthetic peptide, and 13 of 31 patients (42%) receiving the peptide vaccine plus IL-2 had objective cancer responses, and four additional patients had mixed or minor responses. Synthetic peptide vaccines based on the genes encoding cancer antigens hold promise for the development of novel cancer immunotherapies.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Cancer regression in patients receiving immunization with 209-2M peptide in IFA plus IL-2. top left, Regression of multiple lung metastases in a 47-year-old female (patient I in Table 5). bottom left, Regression of two brain metastases in a 42-year-old female (patient k). This patient had four brain metastases all of which underwent significant regression, above, Regression of multiple cutaneous and subcutaneous metastases in a 44-year-old male (patient c). Significant regression was seen by 8 days after starting treatment.
See this image and copyright information in PMC

Comment in

References

    1. Rosenberg SA. The development of new cancer therapies based on the molecular identification of cancer regression antigens. Cancer J. Sci. Am. 1995;1:89–100. - PubMed
    1. Boon T. Tumor antigens recognized by cytolytic T lymphocytes: Present perspectives for specific immunotherapy. Int. J. Cancer. 1993;54:177–180. - PubMed
    1. Rosenberg SA, et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: Preliminary report. N. Engl. J. Med. 1988;319:1676–1680. - PubMed
    1. Rosenberg SA, et al. Treatment of patients with metastatic melanoma using autologous tumor-infiltrating lymphocytes and interleukin-2. J. Natl. Cancer Inst. 1994;86:1159–1166. - PubMed
    1. Kawakami Y, et al. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA. 1994;91:6458–6462. - PMC - PubMed

Publication types